The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)
Official Title: A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer
Study ID: NCT00523315
Brief Summary: To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, Cheonan-si, Chuncheongnam-do, Korea, Republic of
Research Site, Kangnung-si, Gangwon-do, Korea, Republic of
Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of
Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of
Research Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of
Research Site, Anyang-si, Gyunggi-do, Korea, Republic of
Reserach Site, Euijungbu-si, Gyunggi-do, Korea, Republic of
Research Site, Seongnam, Gyunggi-do, Korea, Republic of
Research Site, Suwon, Gyunggi-do, Korea, Republic of
Research Site, Iksan-si, Jeollabuk-do, Korea, Republic of
Research Site, Jeonju, Jeollabuk-do, Korea, Republic of
Research Site, Busan, , Korea, Republic of
Research Site, Daegu, , Korea, Republic of
Research Site, Daejeon, , Korea, Republic of
Research Site, Daejoen, , Korea, Republic of
Research Site, Gwangju, , Korea, Republic of
Research Site, Incheon, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Ulsan, , Korea, Republic of
Name: Joon Woo Bahn
Affiliation: AstraZeneca Korea
Role: STUDY_DIRECTOR